| Literature DB >> 27419134 |
Eun Jin Ahn1, Geun Joo Choi2, Hyun Kang2, Chong Wha Baek2, Yong Hun Jung2, Young Cheol Woo2, Si Ra Bang1.
Abstract
Air-Q® (air-Q) is a supraglottic airway device which can be used as a guidance of intubation in pediatric as well as in adult patients. We evaluated the efficacy and safety of air-Q compared to other airway devices during general anesthesia in pediatric patients by conducting a systematic review and meta-analysis. A total of 10 studies including 789 patients were included in the final analysis. Compared with other supraglottic airway devices, air-Q showed no evidence for a difference in leakage pressure and insertion time. The ease of insertion was significantly lower than other supraglottic airway devices. The success rate of intubation was significantly lower than other airway devices. However, fiberoptic view was better through the air-Q than other supraglottic airway devices. Therefore, air-Q could be a safe substitute for other airway devices and may provide better fiberoptic bronchoscopic view.Entities:
Mesh:
Year: 2016 PMID: 27419134 PMCID: PMC4935900 DOI: 10.1155/2016/6406391
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Summary of studies included.
| Source | Device size | Use of muscle relaxant | Induction method | Maintenance agent |
|---|---|---|---|---|
| Sohn et al. 2014 [ | According to manufacturer guidelines based on the patient's weight | Rocuronium | 8% sevoflurane, 70% nitrous oxide, rocuronium 0.6 mg/kg | Sevoflurane |
|
| ||||
| Jagannathan et al. 2012 [ | Size 2 and size 1.5 | No | Sevoflurane with 70% nitrous oxide and fentanyl 1 | Sevoflurane |
|
| ||||
| Jagannathan et al. 2012 [ | Based on the manufacturer guidelines | Rocuronium | Sevoflurane with 70% nitrous oxide and fentanyl 1 | Sevoflurane |
|
| ||||
| Jagannathan et al. 2012 [ | Air-Q: size 2 and LMA: 2.5 | No | Sevoflurane with 70% nitrous oxide and fentanyl 1 | Sevoflurane with 60% nitrous oxide |
|
| ||||
| Jagannathan et al. 2015 [ | Based on manufacturer guidelines | Rocuronium | 70% nitrous oxide and sevoflurane 8% | Sevoflurane 3% |
|
| ||||
| Kim et al. 2015 [ | Based on manufacturer guidelines | No | Propofol 2 mg/kg or 6% sevoflurane | 3-4% sevoflurane |
|
| ||||
| Girgis et al. 2014 [ | Based on manufacturer guidelines | Atracurium | Premedication with midazolam 0.5 mg·kg, 8% sevoflurane, 100% oxygen, fentanyl 1 | Not reported |
|
| ||||
| Darlong et al. 2014 [ | Depending upon body weight | Atracurium | Sevoflurane 2–8%, fentanyl 1 | Isoflurane 1-2% |
|
| ||||
| Darlong et al. 2015 [ | Depending upon body weight | Atracurium | Sevoflurane 2–8%, fentanyl 1 | Isoflurane 1-2% |
|
| ||||
| Kleine-Brueggeney et al. 2015 [ | Based on manufacturer guidelines | Atracurium | Sevoflurane 6% for inhalation induction, propofol 4 mg/kg or thiopental 6 mg/kg for intravenous induction, fentanyl or alfentanil, atracurium | Not commented |
LMA: laryngeal mask airway; ETT: endotracheal tube.
Figure 1PRISMA flow diagram of the search, inclusion, and exclusion of randomized controlled trials.
Summary of studies included.
| Source | Number of patients | Sex (M/F) | Age | Weight | Height | ASA |
|---|---|---|---|---|---|---|
| Sohn et al. 2014 [ | 80 | Not reported | 8 (6) | 8 (2) | 71 (8) | 1, 2, 3 |
| Jagannathan et al. 2012 [ | 100 | Not reported | 19 (6) | 11 (1) | Not reported | 1, 2 |
| Jagannathan et al. 2012 [ | 120 | 85/35 | 2 (1) | 12 (4) | 89 (23) | 1, 2, 3 |
| Jagannathan et al. 2012 [ | 60 | 38/22 | 7 (2) | 25 (3) | Not reported | 1, 2, 3 |
| Jagannathan et al. 2015 [ | 96 | Not reported | 2.2 | 12.3 | 84.5 | 1, 2, 3 |
| Kim et al. 2015 [ | 79 | 76/3 | 2.8 (1.9) | 14.6 [4.9] | 88.6 [16.8] | 1, 2 |
| Girgis et al. 2014 [ | 60 | 30/20 | 3.9 (1.5) | 16.5 [3.1] | 91.8 [11.2] | 1, 2 |
| Darlong et al. 2014 [ | 50 | 39/11 | 8 | 6.5 (2.1) | 7.2 (1.9) | 1, 2 |
| Darlong et al. 2015 [ | 64 | 45/19 | 8.7 (2.8) | 6.6 (1.7) | Not reported | 1, 2 |
| Kleine-Brueggeney et al. 2015 [ | 80 | 43/37 | 4.3 | 16.3 | 116 | 1, 2, 3 |
ASA: American Society of Anesthesiology Classification; age: years or months; FOB: fiberoptic bronchoscopy.
Summary of studies included.
| Source | Amount and experience of device user | Type of surgery | Allowance of insertion trials | Intervention/control |
|---|---|---|---|---|
| Sohn et al. 2014 [ | Attending or trainee, trainee having minimal prior experience with pediatric fiberoptic bronchoscopes and watched a video outlining the steps for fiberoptic guided tracheal intubation through an air-Q before participating | Elective surgical procedures requiring tracheal intubation under general anaesthesia | 3 | Air-Q/fiberoptic tracheal intubation |
|
| ||||
| Jagannathan et al. 2012 [ | Two anesthesiologists experienced in using both devices | Elective outpatient surgery in the supine position | 2 | Air-Q/LMA-Unique |
|
| ||||
| Jagannathan et al. 2012 [ | Five study investigators who used the air-Q for tracheal intubation in at least 50 patients and who have minimal experience with the Aura-I prior to this study | Elective surgery under general endotracheal anaesthesia | 3 | Air-Q/Aura-I |
|
| ||||
| Jagannathan et al. 2012 [ | Three study investigators experienced in the use of both devices | Elective outpatient surgery with planned airway management with a LMA device | 2 | Air-Q/LMA-Unique |
|
| ||||
| Jagannathan et al. 2015 [ | Anaesthesiology trainees, resident or fellow from clinical anaesthesia 2, 3, or 4 who had not previously performed FOB-guided tracheal intubation through an SGA in children → and received a brief lecture and viewed a video outlining the steps for FOB-guided tracheal intubation through an SGA | Elective surgery under general endotracheal anaesthesia | 3 | Air-Q/i-gel |
|
| ||||
| Kim et al. 2015 [ | Two anesthesiologists experienced in inserting supraglottic airway devices in at least 100 pediatric patients | Elective surgery under general endotracheal anaesthesia | 2 | Air-Q/i-gel |
|
| ||||
| Girgis et al. 2014 [ | Not reported | Elective surgery under general endotracheal anaesthesia | 2 | Air-Q/CobraPLA |
|
| ||||
| Darlong et al. 2014 [ | Not reported | Cataract or glaucoma surgery | 3 | Air-Q/Flexible laryngeal mask |
|
| ||||
| Darlong et al. 2015 [ | Not reported | Elective surgery with tracheal intubation | 3 | Air-Q/Aura-I |
|
| ||||
| Kleine-Brueggeney et al. 2015 [ | Senior anesthesiologists from the pediatric anaesthesia division | Elective ophthalmic surgery | 3 | Air-Q/Aura-I |
Risk of bias in included randomized controlled trials.
| Biases/references | Random sequence generation | Allocation concealment | Incomplete outcome data | Blinding of participants | Blinding of outcome assessment | Selective reporting | Other bias |
|---|---|---|---|---|---|---|---|
| Sohn et al. 2014 [ | Low risk | Unclear | Low risk | Unclear | Unclear | Low risk | Low risk |
| Jagannathan et al. 2012 [ | Low risk | Low risk | Low risk | Unclear | Unclear | Low risk | Low risk |
| Jagannathan et al. 2012 [ | Low risk | Unclear | Low risk | Unclear | Unclear | Low risk | Low risk |
| Jagannathan et al. 2012 [ | Low risk | Low risk | Low risk | Unclear | Unclear | Low risk | Low risk |
| Jagannathan et al. 2015 [ | Low risk | Unclear | Low risk | Unclear | Unclear | Low risk | Low risk |
| Kim et al. 2015 [ | Low risk | Low risk | Low risk | Unclear | Unclear | Low risk | Low risk |
| Girgis et al. 2014 [ | Low risk | Low risk | Low risk | Unclear | Unclear | Low risk | Low risk |
| Darlong et al. 2014 [ | Low risk | Low risk | Low risk | Unclear | Unclear | Low risk | Low risk |
| Darlong et al. 2015 [ | Low risk | Low risk | Low risk | Unclear | Unclear | Low risk | Low risk |
| Kleine-Brueggeney et al. 2015 [ | Low risk | Low risk | Low risk | Unclear | Unclear | Low risk | Low risk |
Figure 2Forest plot for ease of insertion. The figure depicted individual trials as filled squares with relative size of sample size and solid line as the 95% confidence interval of the difference. The diamond shape indicates the pooled estimate and uncertainty for the combined effect.
Figure 3Forest plot for the fiberoptic view of best scenario. The figure depicted individual trials as filled squares with relative size of sample size and solid line as the 95% confidence interval of the difference. The diamond shape indicates the pooled estimate and uncertainty for the combined effect.